Roth MKM lowered the firm’s price target on CervoMed (CRVO) to $4 from $45 and keeps a Buy rating on the shares. The company ...

The latest in health news includes Zealand Pharma's obesity drug trial, a record dengue outbreak in the Americas, CervoMed's ...

CervoMed Inc. (NASDAQ:CRVO) stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b ...

CervoMed Inc.’s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with ...

CervoMed’s dementia drug disappoints in Phase 2: The drugmaker’s neflamapimod missed both the primary and key secondary endpoints in a mid-stage trial of 159 patients with dementia with Lewy bodies.

CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary ...

CervoMed Inc. (CRVO) announced Tuesday that its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia ...

Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks——Favorable ...

Recent headlines in health news spotlight several pharmaceutical developments: AbbVie's Parkinson's drug shows promise in ...

U.S. drug developer CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary goals in a mid-stage clinical trial. The drug, ...

CervoMed on Tuesday said a mid-stage study of its lead program neflamapimod missed its key goals in the degenerative brain disease dementia with Lewy bodies, or DLB.

CervoMed’s ex-Vertex drug has failed to reduce the severity of patients’ dementia in a phase 2 trial, halting plans for a ...